Intellia Therapeutics (NTLA) Tops Q1 EPS by 17c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.10), $0.17 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $16.63 million versus the consensus estimate of $12.79 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Centrus Energy signs $900M DOE contract for uranium enrichment
• OneMedNet files to register resale of up to 11.68M shares